1. Home
  2. SVRN vs BCDA Comparison

SVRN vs BCDA Comparison

Compare SVRN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SVRN

OceanPal Inc.

HOLD

Current Price

$10.37

Market Cap

17.0M

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.07

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVRN
BCDA
Founded
2021
N/A
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
14.1M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
SVRN
BCDA
Price
$10.37
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
14.9K
208.4K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.75
52 Week High
$15.07
$2.29

Technical Indicators

Market Signals
Indicator
SVRN
BCDA
Relative Strength Index (RSI) 78.91 57.26
Support Level $8.16 $0.80
Resistance Level $12.73 $1.28
Average True Range (ATR) 0.79 0.07
MACD 0.33 0.01
Stochastic Oscillator 90.94 57.19

Price Performance

Historical Comparison
SVRN
BCDA

About SVRN OceanPal Inc.

Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: